09:38 AM EDT, 08/19/2024 (MT Newswires) -- ChromaDex ( CDXC ) said Monday it has been awarded a US patent for the disodium salt form of dihydronicotinamide mononucleotide, or NMNH, a nicotinamide adenine dinucleotide, or NAD+, precursor.

The company said the patent, co-owned with Queen's University Belfast, supports ChromaDex's ( CDXC ) position in the NAD+ precursor market by giving it exclusive rights to this specific salt form of NMNH.

While NMNH has shown potential in supporting NAD+ levels in preclinical studies, questions remain about its safety and effectiveness as a dietary supplement, ChromaDex ( CDXC ) added.

Price: 3.30, Change: -0.04, Percent Change: -1.20